The Spallanzani Institute begins testing the Italian coronavirus vaccine
Well-being — di Martina Girola
The Lazzaro Spallanzani Institute in Rome has begun trials of the first Italian vaccine against coronavirus.

The Lazzaro Spallanzani Institute in Rome has begun trials of the first Italian vaccine against coronavirus.
On Monday 24 August, at the Lazzaro Spallanzani National Institute for Infectious Diseases in Rome — the country's reference point since the very first moments of the health emergency — the first dose of the Italian experimental vaccine against coronavirus, called Grad-Cov-2, was administered. The first person to receive it was a fifty-year-old woman who hopes her gesture "can serve research and make people more responsible." With this administration, the initial testing phase — which will analyse the vaccine's safety — officially gets under way. The hope is to obtain a safe drug by spring 2021.
More than five thousand people volunteered to take part in the Spallanzani's trial process to test the new coronavirus vaccine produced by the company Reithera. From among them, 90 volunteers were selected to take part in phase one: half are aged between 18 and 55; the other half are over 65.
This week they are being given the first dose of Grad-Cov-2. This will be followed by a meticulous monitoring phase to ensure that the drug is safe and does not produce dangerous side effects. This phase must also confirm that the dose is immunogenic — that is, capable of prompting the body to produce antibodies able to block viral replication.
"The second [phase, ed.], with 500–1,000 volunteers, could take place in Italy as soon as the results of the first phase are available. For the third we are thinking of countries with a high incidence of cases, involving 10,000 people. The choice will depend on how the epidemic evolves in autumn," said Antonella Folgori, chief executive of Reithera, the company that developed the drug, in an interview with Corriere della Sera. "The tests will be carried out at the Spallanzani and at the clinical research centre in Verona. For phase two we are setting up new sites in Piacenza and Cremona," she added.
"Ours is a complex and rigorous protocol that will guarantee the highest level of safety," explained Giuseppe Ippolito, scientific director of the Spallanzani and one of the key figures of recent months. "It will take at least 24 weeks to complete the first phase of human trials of the vaccine. We will then move on to the second phase, for which we are already preparing. Playing with timelines and cutting back on trials is not helpful."
If everything were to proceed correctly, a vaccine could be available by spring 2021.
"We strongly believe in the vaccine as a common good. The drug will be in the public domain and, once the trial phase is complete, it will be available to all those who need it," added Nicola Zingaretti, president of the Lazio region, one of the regions currently recording the highest numbers of new infections.
Francesco Vaia, health director of the Spallanzani, finally came out against the possibility of making the vaccine compulsory: "I think it would be wrong — it is not right to compel people — but it will be up to us to convince citizens of the vaccine's merits."
The vaccine is delivered into the body via a gorilla adenovirus — a virus that causes colds in animals — which has been appropriately deactivated and modified so as to prompt the human immune system to defend itself against Sars-Cov-2.
This vaccine works in a very similar way to the one being trialled at Oxford, where the Italian company Irbm is also collaborating. ChAdOx1 nCoV-19, as the British vaccine is called, is one of the most advanced in the trial phases currently under way in the United Kingdom, Brazil and South Africa. The results of phase three are expected in September, and will provide more precise indications as to any potential commercialisation.